U.S. court rules against Bayer's Yasmin patent

Headline Legal News Posted on

A U.S. district court ruled against the validity of Bayer Schering Pharma's patent for its contraceptive drug Yasmin, the German drug company said late on Monday.

This was the result of a patent challenge by generic manufacturer Barr Laboratories, Bayer said in a statement.

"Bayer disagrees with the court's decision and will consider its legal options in this regard," the company added.

Bayer Schering's contraceptive drug Yasmin has annual sales of more than one billion euros. Sales of Yasmin in the United States came in at 321 million euros ($486.9 million) last year, it said.

Legal News Media

Legal News is the top headline legal news provider for lawyers and legalprofessionals. Read law articles and breaking news from law firm's across the United States to get the latest updates. We reserve the right, at our discretion, to change, modify, add, or remove portions of the site at any time. Your This site is solely for your personal use. You are, of course, welcome to print or otherwise copy material from this site for your personal use. However, you may not distribute, exchange, modify, sell or transmit anything you copy from this Site, including but not limited to any text, images, audio and video, for any business, commercial or public purpose. Any unauthorized use of the text, images, audio and video may violate copyright laws, trademark laws, the laws of privacy and publicity and civil and criminal statutes.

 

American Bar Association – Start and Run a Law Firm

NewYorkStateBar.com – Starting a Law Firm

CPA Website Designs